Radiopharm Draws $8M RDTI-Backed Advance From Rockford Capital
RADX is trading near its 52-week low of $0.9 (5.4% above the low).
Summary
Radiopharm received $8M from Rockford Capital as an early draw against its anticipated FY26 Australian R&D tax incentive, secured against that refund and repayable by 26 October 2027. For a company that recently disclosed a going-concern warning on A$4.14M of cash, the non-dilutive funding extends runway.
Key Events · Financing and Capital Events · RADX
-
Rockford Advance Secured Against RDTI
Radiopharm received $8,000,000 from Rockford Capital under a facility secured against its anticipated FY26 Australian R&D Tax Incentive refund.
-
Non-Dilutive Cash, But Borrowed
The funds support the clinical trial pipeline and general working capital without issuing shares, but carry interest at a commercial rate and are repayable by 26 October 2027, with the FY26 RDTI refund effectively pre-committed to the lender.
-
Runway Relief After Going-Concern Warning
The advance follows the FY2026 annual report's going-concern warning on a cash balance of A$4.14M, materially extending near-term liquidity.
-
Early Repayment Permitted
The facility can be repaid at any time without penalty before the 26 October 2027 maturity.
Analysis · RADX · Life Sciences
Radiopharm has pulled forward $8M of its expected FY26 Australian R&D tax incentive through a Rockford Capital facility secured against that refund. With cash of just A$4.14M and a going-concern warning disclosed in the FY2026 annual report, the move roughly triples near-term liquidity and funds the clinical pipeline without issuing equity at depressed prices. The trade-off: the FY26 RDTI refund is now pre-committed to Rockford, interest accrues at a commercial rate, and repayment is due by 26 October 2027. In short, the cash is borrowed, not earned, and the eventual tax refund will largely flow to the lender.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.9M. The 52-week trading range was $0.90 to $16.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.